ATE520691T1 - Shp-2-hemmer, pharmazeutische zusammensetzung damit und ihre verwendung zur behandlung phosphatase-vermittelter erkrankungen - Google Patents
Shp-2-hemmer, pharmazeutische zusammensetzung damit und ihre verwendung zur behandlung phosphatase-vermittelter erkrankungenInfo
- Publication number
- ATE520691T1 ATE520691T1 AT06763473T AT06763473T ATE520691T1 AT E520691 T1 ATE520691 T1 AT E520691T1 AT 06763473 T AT06763473 T AT 06763473T AT 06763473 T AT06763473 T AT 06763473T AT E520691 T1 ATE520691 T1 AT E520691T1
- Authority
- AT
- Austria
- Prior art keywords
- inhibitors
- phosphatase
- shp
- treating
- pharmaceutical compositions
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 title 1
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000026350 Inborn Genetic disease Diseases 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 abstract 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 abstract 1
- 230000002491 angiogenic effect Effects 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000016361 genetic disease Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 239000003806 protein tyrosine phosphatase inhibitor Substances 0.000 abstract 1
- 150000003384 small molecules Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
- C07D231/46—Oxygen atom in position 3 or 5 and nitrogen atom in position 4
- C07D231/48—Oxygen atom in position 3 or 5 and nitrogen atom in position 4 with hydrocarbon radicals attached to said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05090160A EP1728790A1 (de) | 2005-06-01 | 2005-06-01 | Shp-2-Inhibitoren, Arzneimittel, die sie enthalten sowie deren Verwendung zur Behandlung von Phosphatasen-vermittelten Krankheiten |
| PCT/EP2006/062852 WO2006128909A1 (en) | 2005-06-01 | 2006-06-01 | Shp-2 inhibitors, pharmaceutical compositions comprising them and their use for treating phosphatase-mediated diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE520691T1 true ATE520691T1 (de) | 2011-09-15 |
Family
ID=35033628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06763473T ATE520691T1 (de) | 2005-06-01 | 2006-06-01 | Shp-2-hemmer, pharmazeutische zusammensetzung damit und ihre verwendung zur behandlung phosphatase-vermittelter erkrankungen |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US7868185B2 (de) |
| EP (2) | EP1728790A1 (de) |
| JP (1) | JP5153621B2 (de) |
| AT (1) | ATE520691T1 (de) |
| WO (1) | WO2006128909A1 (de) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9174969B2 (en) | 2008-07-21 | 2015-11-03 | University Of South Florida | Indoline scaffold SHP-2 inhibitors and cancer treatment method |
| WO2011110546A2 (en) * | 2010-03-08 | 2011-09-15 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Pharmaceutical composition comprising an inhibitor of shp-2 and screening method |
| EP2552451A1 (de) * | 2010-03-29 | 2013-02-06 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Proteintyrosinphosphatase, nicht-rezeptor typ 11 (ptpn11) und tumorinitiierende zellen |
| WO2012041524A1 (en) * | 2010-10-01 | 2012-04-05 | Max-Delbrück-Centrum Für Molekulare Medizin (Mdc) | Hydrazonopyrazolones as protein tyrosine phosphatase inhibitors |
| WO2012168259A1 (en) * | 2011-06-06 | 2012-12-13 | Novartis Forschungsstiftung, Zweigniederlassung | Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer |
| US8987461B2 (en) | 2012-12-06 | 2015-03-24 | Quanticel Pharmaceuticals, Inc. | Histone demethylase inhibitors |
| EP3456725A1 (de) | 2017-09-13 | 2019-03-20 | Freie Universität Berlin | Pentafluorophosphatderivate, deren verwendungen und ein entsprechendes herstellungsverfahren |
| US11110171B2 (en) * | 2017-12-21 | 2021-09-07 | New York University | PD-1 related cancer therapy |
| EP3886854A4 (de) | 2018-11-30 | 2022-07-06 | Nuvation Bio Inc. | Pyrrol- und pyrazolverbindungen und verfahren zu deren verwendung |
| CA3112129A1 (en) | 2018-12-05 | 2020-06-11 | Mirati Therapeutics, Inc. | Combination therapies |
| WO2024249284A2 (en) * | 2023-05-26 | 2024-12-05 | Ipsen Pharma S.A.S. | Bax activators and use thereof |
| WO2025034919A1 (en) | 2023-08-08 | 2025-02-13 | Quanta Therapeutics, Inc. | Combination therapies with kras modulators |
| WO2025106901A1 (en) | 2023-11-17 | 2025-05-22 | Quanta Therapeutics, Inc. | Combination cancer therapies with a kras modulator and an rtk-mapk pathway inhibitor |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01255855A (ja) * | 1988-04-05 | 1989-10-12 | Konica Corp | フロートガラス支持体を有するハロゲン化銀写真感光材料 |
| US6200807B1 (en) | 1999-07-21 | 2001-03-13 | Isis Pharmaceuticals Inc. | Antisense inhibition of SHP-2 expression |
| AU2003239897A1 (en) | 2002-05-23 | 2003-12-12 | Ceptyr, Inc. | Modulation of ptp1b signal transduction by rna interference |
| AU2003300447B2 (en) | 2002-12-30 | 2009-09-03 | Vertex Pharmaceuticals Incorporated | Sulfhydantoins as phosphate isosteres for use as phosphatase inhibitors in the treatment of cancer and autoimmune disorders |
-
2005
- 2005-06-01 EP EP05090160A patent/EP1728790A1/de not_active Withdrawn
-
2006
- 2006-06-01 AT AT06763473T patent/ATE520691T1/de not_active IP Right Cessation
- 2006-06-01 EP EP06763473A patent/EP1885717B1/de not_active Not-in-force
- 2006-06-01 WO PCT/EP2006/062852 patent/WO2006128909A1/en not_active Ceased
- 2006-06-01 US US11/916,111 patent/US7868185B2/en not_active Expired - Fee Related
- 2006-06-01 JP JP2008514113A patent/JP5153621B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US7868185B2 (en) | 2011-01-11 |
| EP1728790A1 (de) | 2006-12-06 |
| EP1885717B1 (de) | 2011-08-17 |
| JP2008545735A (ja) | 2008-12-18 |
| WO2006128909A1 (en) | 2006-12-07 |
| JP5153621B2 (ja) | 2013-02-27 |
| EP1885717A1 (de) | 2008-02-13 |
| US20080194563A1 (en) | 2008-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE384526T1 (de) | N-(((((1,3-thiazol-2- yl)amino)carbonyl)phenyl)sulphonyl)phenylalanin derivate und verwandte verbindungen zur behandlung von diabetes | |
| NO20055129L (no) | Fenylsubstituerte karboksylsyrer | |
| DE602004030222D1 (de) | 2-oxo-1,3,5-perhydrotriazapinderivate, die sich zur behandlung von hyperproliferativen, angiogenen und entzündlichen erkrankungen eignen | |
| CY1108146T1 (el) | ΑΝΑΣΤΟΛΕΙΣ ΤΗΣ β-ΑΜΙΝΟ-ΕΤΕΡΟΚΥΚΛΙΚΗΣ-ΔΙΠΕΠΤΙΔΥΛΙΚΗΣ ΠΕΠΤΙΔΑΣΗΣ ΓΙΑ ΤΗΝ ΑΓΩΓΗ Ή ΠΡΟΛΗΨΗ ΤΟΥ ΔΙΑΒΗΤΗ | |
| ATE506951T1 (de) | Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit | |
| EP1562897A4 (de) | Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer | |
| DE602004031614D1 (de) | Verwendung von (3.2.0) heterocyclischen verbindungen und ihren analoga zur behandlung von krebs | |
| DE60331537D1 (de) | Kombinationen zur behandlung von multiplem myelom | |
| ATE482722T1 (de) | Therapeutische verwendung von anti-cs1- antikörpern | |
| DE60330485D1 (de) | Zur behandlung von diabetes | |
| ATE520691T1 (de) | Shp-2-hemmer, pharmazeutische zusammensetzung damit und ihre verwendung zur behandlung phosphatase-vermittelter erkrankungen | |
| NO20054957L (no) | Subtituerte karboksylsyrer | |
| ATE517861T1 (de) | Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
| ATE396174T1 (de) | Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten | |
| ATE538651T1 (de) | Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
| EA200601212A1 (ru) | Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение | |
| ATE452884T1 (de) | Arylmethylamin-derivate zur verwendung als inhibitoren von tryptase | |
| ATE456955T1 (de) | Verwendung von cyclodextrin zur behandlung und vorbeugung von entzündlichen bronchialerkrankungen | |
| BR0312768A (pt) | Compostos de 5-ariltetrazol, composições do mesmo e usos dos mesmos | |
| DE602004020042D1 (de) | er SSRI zur Behandlung von Stimmungs- oder Angststörungen | |
| ATE424208T1 (de) | Proteinkinaseinhibitoren | |
| ATE538796T1 (de) | Piperidin- und pyrrolidin-beta-secretase-hemmer zur behandlung von alzheimer-krankheit | |
| ATE382347T1 (de) | Pharmazeutische zusammensetzung zur verwendung bei der behandlung von malignen erkrankungen, umfassend eine kombination aus bisphosphonaten, einem cox-2 inhibitor und einem taxol | |
| DE602005024192D1 (de) | Chinazolinderivate als Phosphodiesterasehemmer zur Verwendung für die Behandlung peripherer Arterienerkrankungen | |
| DE60219680D1 (de) | Amin-1,2- und -1,3-diolverbindungen und deren verwendung zur behandlung von alzheimer-krankheit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |